Journal profile · ONCOLOGY
Journal of Cancer Metastasis and Treatment
ISSN 2394-4722 · eISSN 2454-2857 · OAE Publishing Inc.
Journal of Cancer Metastasis and Treatment: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.6 (journal website); fully open access; APC about USD 2,600; review about 4 days (submission to first decision, publisher); 28 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Journal of Cancer Metastasis and Treatment is published by OAE Publishing Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Cells and Metastasis, Cancer Immunotherapy and Biomarkers and Cancer Genomics and Diagnostics, together about 18.9% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Cancer Metastasis and Treatment (JCMT) is an international, peer-reviewed, open-access journal dedicated to advancing research on cancer progression, metastasis, and therapeutic strategies. The journal publishes high-quality basic, translational, and clinical studies across solid and hematologic malignancies, with a particular emphasis on metastasis-driven disease biology and management. JCMT aims to bridge fundamental discoveries with clinical applications to accelerate innovation and improve outcomes for patients with advanced cancer. Core areas of interest include: Cancer biology and progression: Molecular, cellular, and genetic mechanisms underlying tumor initiation, evolution, and metastatic disseminationMetastasis research: Biology of metastatic spread, tumor microenvironment interactions, and strategies for metastasis prevention and interventionTherapeutic approaches: Systemic therapies (chemotherapy, targeted therapy, immunotherapy), radiotherapy, and surgical management of primary and metastatic diseaseClinical outcomes and prevention: Epidemiology, risk assessment, and strategies for early detection and prevention of cancer progression Interdisciplinary and emerging areas are strongly encouraged, including: Bioinformatics and computational biology for biomarker and therapeutic target discoverySystems and multi-omics approaches to tumor heterogeneity and microenvironment dynamicsPrecision oncology and personalized medicineImmunotherapy innovations (e.g., checkpoint blockade, cell-based therapies, cancer vaccines)Nanotechnology and advanced drug delivery systemsBiomedical engineering and novel diagnostic or minimally invasive technologies JCMT welcomes a broad range of article types, including Original Articles, Reviews, Systematic Reviews, Meta-Analyses, Technical Notes, Commentaries, Editorials, Perspectives, and Letters to the Editor. Mission:By integrating fundamental metastasis research with state-of-the-art basic and clinical advances, JCMT seeks to accelerate scientific and clinical progress, improve survival, and enhance the quality of life for patients with metastatic cancer.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Ciro IsidoroPublisher website
Editorial board by country: 29 in mainland China (about 35%); most named Mainland China 29, United States 15, Italy 10, United Kingdom 4, Germany 4 (83 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Cells and MetastasisMedicine6.6%
- Cancer Immunotherapy and BiomarkersMedicine6.3%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6%
- Cancer Diagnosis and TreatmentMedicine6%
- Lung Cancer Research StudiesMedicine5.7%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology5%
- Brain Metastases and TreatmentMedicine4.4%
- Gastric Cancer Management and OutcomesMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.6Publisher website ·
- CiteScore 2026-06
- 1.9LetPub ·
- CiteScore (publisher)
- 1.9Publisher website ·
- SJR 2026-06
- 0.34LetPub ·
- SNIP 2026-06
- 0.26LetPub ·
- h-index
- 31OpenAlex ·
- i10-index
- 133OpenAlex ·
- 2-year mean citedness
- 1.46OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 98.97%LetPub ·
Volume
- Articles per year
- 28LetPub ·
- Articles per year (publisher) 2027
- 2,027Publisher website ·
- Articles per year (publisher) 2026
- 2,026Publisher website ·
- Downloads per year (publisher)
- 1,017,673Publisher website ·
Articles by year OpenAlex count · 575 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 14 | 14 | 4 |
| 2025 | 28 | 28 | 23 |
| 2024 | 32 | 32 | 81 |
| 2023 | 42 | 42 | 116 |
| 2022 | 49 | 49 | 197 |
| 2021 | 71 | 71 | 485 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Desk decision
- 4 daysPublisher website ·
- Submission to first decision
- 4 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 2,600 | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- USD 2,600
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteWhat to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 3–8
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Graphical abstract
- Required
- Cover letter
- Required
- Not considered
- title; language; equations
Article types accepted7
- commentaryThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
- meta-analysisThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
- mini reviewThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
- original articleThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
- reviewThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
- review articleThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
- systematic reviewThere is no restriction on the number of figures, tables and references, provided that the manuscript is concise and comprehensive. The journal publishes Origin…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use 2.3.3.4 AI and AI-assisted tools Statement
Authors should disclose in their manuscript the use of AI and AI-assisted technologies. Declaring the use of these technologies supports transparency and trust between authors, readers, reviewers, editors and contributors and facilitates compliance with the terms of use of the relevant tool or technology.If the manuscript does not involve this issue, state "Not applicable." in this section.
Source ↗Publisher website ·- Authorship 4. Authorship
Authorship credit of JCMT should be solely based on substantial contributions to a published study, as specified in the following four criteria:1. Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work;2. Drafting the work or revising it critically for important intellectual content;3. Final approval of the version to…
Source ↗Publisher website ·- Conflicts of interest 2.3.3.6 Conflicts of Interest
Authors must declare any potential conflicts of interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. If there are no conflicts of interest, please state "All authors declared that there are no conflicts of interest." in this section. Some authors may be bound by confidentiality agreements. In such cases, in place of itemiz…
Source ↗Publisher website ·- Data availability 2.3.3.3 Availability of Data and Materials
In order to maintain the integrity, transparency and reproducibility of research records, authors should include this section in their manuscripts, detailing where the data supporting their findings can be found. Data can be deposited into data repositories or published as supplementary information in the journal. Authors who cannot share their data should state that the data will not be shared an…
Source ↗Publisher website ·- Publication ethics 2.3.3.7 Ethical Approval and Consent to Participate
Research involving human subjects, human material or human data must be performed in accordance with the Declaration of Helsinki and approved by an appropriate ethics committee. An informed consent to participate in the study should also be obtained from participants, or their parents or legal guardians for children under 16. A statement detailing the name of the ethics committee (including the re…
Source ↗Publisher website ·- License & copyright 1.2 Open Access and Copyright
The journal adopts Gold Open Access publishing model and distributes content under the Creative Commons Attribution 4.0 International License. Copyright is retained by authors. Please make sure that you are well aware of these policies.
Source ↗Publisher website ·- Open access 1.2 Open Access and Copyright
The journal adopts Gold Open Access publishing model and distributes content under the Creative Commons Attribution 4.0 International License. Copyright is retained by authors. Please make sure that you are well aware of these policies.
Source ↗Publisher website ·- Peer review 7.3 AI Use in Peer Review
Confidentiality requirements: Reviewers must not upload manuscripts/materials to AI platforms, as this: 1. Violates OAE’s confidentiality policies2. Risks intellectual property infringement3. May compromise personal data in identifiable content Review integrity standards: Peer review must remain human-driven – AI tools cannot replace critical scholarly judgment.Reviewers must not use AI for manusc…
Source ↗Publisher website ·- Trial registration / reporting guidelines 3.1.5 Trial Registration
JCMT requires all authors to register all relevant clinical trials that are reported in manuscripts submitted. JCMT follows the World Health Organization (WHO)'s definition of clinical trials: "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- OAE Publishing Inc.
- ISSN
- 2394-4722
- Electronic ISSN
- 2454-2857
- Official links
- Journal homepage ↗OpenAlex
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Cancer Metastasis and Treatment
What CAS zone is Journal of Cancer Metastasis and Treatment in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Cancer Metastasis and Treatment is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Cancer Metastasis and Treatment?
The journal's website gives an impact factor of 1.6; this is the journal's own figure, as LetPub lists none for it; CiteScore 1.9, h-index 31.
How long does peer review take at Journal of Cancer Metastasis and Treatment?
The publisher reports about 4 days (submission to first decision); first decisions include desk rejections. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Cancer Metastasis and Treatment?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 3–8; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Cancer Metastasis and Treatment based?
Of the 83 board members whose country the journal's board page names, 29 (about 35%) are in mainland China; the countries named most often are Mainland China (29), United States (15) and Italy (10). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Cancer Metastasis and Treatment?
According to LetPub and DOAJ records, Journal of Cancer Metastasis and Treatment is indexed in ESCI and Scopus.
Is Journal of Cancer Metastasis and Treatment open access, and what is the APC?
Journal of Cancer Metastasis and Treatment is a fully open-access journal. APC about USD 2,600.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .